Suppr超能文献

相似文献

1
HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3735-44. doi: 10.1073/pnas.1602079113. Epub 2016 Jun 14.
3
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080. doi: 10.1073/pnas.1814634116. Epub 2019 Mar 13.
6
Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Oncotarget. 2015 May 30;6(15):13049-59. doi: 10.18632/oncotarget.3790.
8
Mutations and deletions of PRC2 in prostate cancer.
Bioessays. 2016 May;38(5):446-54. doi: 10.1002/bies.201500162. Epub 2016 Mar 22.
9
Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer.
PLoS One. 2016 Oct 20;11(10):e0165005. doi: 10.1371/journal.pone.0165005. eCollection 2016.
10
Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.
J Cancer Res Ther. 2021 Apr-Jun;17(2):311-326. doi: 10.4103/jcrt.JCRT_1090_19.

引用本文的文献

2
Role of epigenetics in paediatric cancer pathogenesis & drug resistance.
Br J Cancer. 2025 May;132(9):757-769. doi: 10.1038/s41416-025-02961-2. Epub 2025 Mar 7.
3
Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.
Funct Integr Genomics. 2025 Mar 6;25(1):53. doi: 10.1007/s10142-025-01563-8.
4
Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities.
Ther Adv Med Oncol. 2025 Jan 7;17:17588359241306026. doi: 10.1177/17588359241306026. eCollection 2025.
5
Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review.
Life (Basel). 2024 Dec 11;14(12):1645. doi: 10.3390/life14121645.
7
Multi-output prediction of dose-response curves enables drug repositioning and biomarker discovery.
NPJ Precis Oncol. 2024 Sep 20;8(1):209. doi: 10.1038/s41698-024-00691-x.
8
EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.
Oncogene. 2024 Aug;43(36):2722-2736. doi: 10.1038/s41388-024-03119-9. Epub 2024 Aug 7.
9
Role of EZH2-mediated epigenetic modification on vascular smooth muscle in cardiovascular diseases: A mini-review.
Front Pharmacol. 2024 Jun 27;15:1416992. doi: 10.3389/fphar.2024.1416992. eCollection 2024.
10
Hypoxia makes EZH2 inhibitor not easy-advances of crosstalk between HIF and EZH2.
Life Metab. 2024 Aug;3(4). doi: 10.1093/lifemeta/loae017. Epub 2024 May 6.

本文引用的文献

3
Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis.
Genes Dev. 2015 Dec 15;29(24):2547-62. doi: 10.1101/gad.269522.115. Epub 2015 Dec 4.
4
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.
J Clin Invest. 2015 Oct 26;125(12):4375-90. doi: 10.1172/JCI80325.
5
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6215-23. doi: 10.1073/pnas.1520032112. Epub 2015 Oct 28.
6
Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis.
Biomed Pharmacother. 2015 Oct;75:218-25. doi: 10.1016/j.biopha.2015.07.038. Epub 2015 Aug 10.
7
Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study.
Breast Cancer Res Treat. 2014 Oct;147(3):639-51. doi: 10.1007/s10549-014-3089-1. Epub 2014 Sep 16.
9
EZH2 expands breast stem cells through activation of NOTCH1 signaling.
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3098-103. doi: 10.1073/pnas.1308953111. Epub 2014 Feb 10.
10
Role of hypoxia-inducible factors in breast cancer metastasis.
Future Oncol. 2013 Nov;9(11):1623-36. doi: 10.2217/fon.13.92.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验